Wang S, Ma P, Zhang S, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020;63(10):2102-2111.
Zhang B, Liu S, Zhang L, Dong Y, Zhang S. Admission fasting blood glucose predicts 30-day poor outcome in patients hospitalized for COVID-19 pneumonia. Diabetes Obes Metab. 2020. https://doi.org/10.1111/dom.14132.
Novak M, Vetvicka V. Glucans as biological response modifiers. Endocr Metab Immune Disord Drug Targets. 2009;9(1):67–75.
CAS
Article
Google Scholar
Sobieralski K, Siwulski M, Lisiecka J, JĊdryczka M, Sas-Golak I, FruĪyĔska-JóĨwiak D. Fungi-Derived β-Glucans as a component of functional food. Acta Sci Pol Hortorum Cultus. 2012;11(4):111–28.
Google Scholar
Chen J, Raymond K. Beta-glucans in the treatment of diabetes and associated cardiovascular risks. Vasc Health Risk Manag. 2008;4:1265–72.
CAS
Article
Google Scholar
El Khoury D, Cuda C, Luhovyy BL, Anderson GH. Beta glucan: health benefits in obesity and metabolic syndrome. J Nutr Metab. 2012;2012:851362.
PubMed
Google Scholar
Cao Y, Zou S, Xu H, et al. Hypoglycemic activity of the Baker’s yeast β-glucan in obese/type 2 diabetic mice and the underlying mechanism. Mol Nutr Food Res. 2016;60:2678–90.
CAS
Article
Google Scholar
Francelino Andrade E, Vieira Lobato R, Vasques Araújo T, et al. Effect of beta-glucans in the control of blood glucose levels of diabetic patients: a systematic review. Nutr Hosp. 2014;31:170–7.
PubMed
Google Scholar
Ikewaki N, Fujii N, Onaka T, Ikewaki S, Inoko H. Immunological actions of Sophy beta-glucan (beta-1,3 – 1,6 glucan), currently available commercially as a health food supplement. Microbiol Immunol. 2007;51:861–73.
CAS
Article
Google Scholar
Vetvicka V, Vetvickova J. Comparison of immunological effects of commercially available beta-glucans: part III. Int Clin Pathol J. 2016;2:78–83.
Google Scholar
Li X, Wang J, Wang W, Liu C, Sun S, Gu J, Wang X, Boraschi D, Huang Y, Qu D. Immunomodulatory activity of a novel, synthetic beta-glucan (β-glu6) in murine macrophages and human peripheral blood mononuclear cells. PLoS One. 2013;8:e80399.
CAS
Article
Google Scholar
Yano et al. Sophy Beta-Glucan is effective in alleviating increased blood sugar levels. Abstract presented at the 55th Conference of the Japanese Society of Nutrition and Dietetics 2008.
Dedeepiya VD, Sivaraman G, Venkatesh AP, et al. Potential effects of nichi glucan as a food supplement for diabetes mellitus and hyperlipidemia: preliminary findings from the study on three patients from India. Case Rep Med. 2012;2012:895370.
Article
Google Scholar
Type 2 diabetes: prevention in people at high risk. NICE Public Health Guideline 38 – NICE. Published July 12, 2012. (Available from https://www.nice.org.uk/guidance/ph38) [Accessed 1st Oct 2020]
Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med. 2012;2012:918267.
PubMed
PubMed Central
Google Scholar
Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999;26:259–65.
CAS
Article
Google Scholar
Rao KS, Suryaprakash V, Senthilkumar R, et al. Role of Immune Dysregulation in Increased Mortality Among a Specific Subset of COVID-19 Patients and Immune-Enhancement Strategies for Combatting Through Nutritional Supplements. Front Immunol. 2020;11:154.
Article
Google Scholar
Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med. 1996;28:419–26.
CAS
Article
Google Scholar
Murphy EJ, Masterson C, Rezoagli E, et al. β-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies. Sci Total Environ. 2020;732:139330.
CAS
Article
Google Scholar
Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013;4:37.
Article
Google Scholar
Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18:1–14.
CAS
Article
Google Scholar
Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142.
El-Kashoury, Fattah SM, Ramadan L, El-Denshary ES. The Role of Yeast Beta Glucan on Blood Coagulation in Streptozotocin-Induced Diabetes and Irradiated Rats. 2016. Available from https://www.semanticscholar.org/paper/The-Role-of-Yeast-Beta-Glucan-on-Blood-Coagulation-El-Kashoury-Fatah/6f68a9067831eebb0015c2961882d1e91a89e84f. [Accessed 1st October, 2020].
de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de Azevêdo Silva J. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020;14:597–600.
Article
Google Scholar
Petit J, Bailey EC, Wheeler RT, de Oliveira CAF, Forlenza M, Wiegertjes GF. Studies Into β-Glucan Recognition in Fish Suggests a Key Role for the C-Type Lectin Pathway. Front Immunol. 2019;10:280.
CAS
Article
Google Scholar
Adachi Y, Ishii T, Ikeda Y, Hoshino A, Tamura H, Aketagawa J, Tanaka S, Ohno N. Characterization of beta-glucan recognition site on C-type lectin, dectin 1. Infect Immun. 2004;72:4159–71.
CAS
Article
Google Scholar
Ikewaki N, Rao K, Archibold AD et al. Coagulopathy associated with COVID-19 – Perspectives & Preventive strategies using a biological response modifier Glucan. Thrombosis J 2020;18(27). https://doi.org/10.1186/s12959-020-00239-6